Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

被引:0
作者
Jin Sun Lee
Susan E. Yost
Suzette Blanchard
Daniel Schmolze
Hongwei Holly Yin
Raju Pillai
Kim Robinson
Aileen Tang
Norma Martinez
Jana Portnow
Wei Wen
John H. Yim
Heather Ann Brauer
Yuqi Ren
Thehang Luu
Joanne Mortimer
Yuan Yuan
机构
[1] City of Hope National Medical Center and Beckman Research Institute,Department of Medical Oncology & Therapeutics Research
[2] City of Hope National Medical Center and Beckman Research Institute,Department of Biostatistics
[3] City of Hope National Medical Center and Beckman Research Institute,Department of Pathology
[4] City of Hope National Medical Center and Beckman Research Institute,Department of Surgery
[5] NanoString Technologies,undefined
[6] Inc.,undefined
[7] OncoGambit,undefined
来源
Breast Cancer Research | / 21卷
关键词
Phase I trial; Eribulin; Everolimus; Metastatic TNBC;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 414 条
[1]  
Carey LA(2006)Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492-2502
[2]  
Perou CM(2015)Triple-negative breast cancer: new perspectives for targeted therapies OncoTargets Ther 8 177-2767
[3]  
Livasy CA(2011)Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 121 2750-1887
[4]  
Dressler LG(2012)Dissecting the heterogeneity of triple-negative breast cancer J Clin Oncol 30 1879-5540
[5]  
Cowan D(2013)Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes Clin Cancer Res 19 5533-1698
[6]  
Conway K(2014)Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer Clinical Cancer Research 21 1688-1281
[7]  
Karaca G(2008)Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275-122
[8]  
Troester MA(2011)Current treatment options in triple negative breast cancer Breast Dis 32 99-533
[9]  
Tse CK(2017)Olaparib for metastatic breast cancer in patients with a germline BRCA mutation N Engl J Med 377 523-763
[10]  
Edmiston S(2018)Talazoparib in patients with advanced breast cancer and a germline BRCA mutation N Engl J Med 379 753-2467